Med Fusion has entered into a market development agreement to validate the clinical utility of Theranostics Health's TheraLink assays for use in patients with malignant diseases.
TheraLink assays are designed to measure the activation status of signal transduction pathways of each individual and provide personalized treatment to each patient.
Under the agreement, both the companies will work together to provide clinical validation of the TheraLink assays through clinical trials conducted by med fusion as well as through other oncology practices associated with med fusion.
In addition, the companies will jointly conduct promotional, marketing and sales-related efforts, technology integration, as well as other activities aimed at the clinical services, clinical trials, diagnostic, theranostic and personalized healthcare markets.
Med Fusion chief executive officer Keith Laughman said that the alliance "further supports med fusion's current and future collaborations as it continues to execute its targeted diagnostics initiatives."
Theranostics Health president and CEO Glenn Hoke said the company is looking forward to support med fusion' patient care goals.
"This agreement will allow med fusion to deliver critical information to doctors by providing a molecular snapshot of their patient's tumor, helping doctors provide their patients with the right therapy and ensuring that patients receive the best care possible," Hoke added.
